歌生物科学公司开启了3395亿美元的IPO,为675多名客户提供药物开发服务. Anthem Biosciences opens a ₹3,395 crore IPO, offering drug development services to over 675 clients.

Anthem Biosciences, 一家以孟加拉为基地的毒品开发公司, 于7月14日开业3,395 crore IPO, 股价在540-570之间。 Anthem Biosciences, a Bengaluru-based drug development firm, opens its ₹3,395 crore IPO on July 14, with shares priced between ₹540-570. 该公司为毒品的发现和制造提供端对端服务,具有良好的记录,有675多个客户和8 000个项目。 The company offers end-to-end services for drug discovery and manufacturing and has a strong track record with over 675 clients and 8,000 projects. 尽管增长强劲,但国歌面临风险,因为客户和地理集中程度高,而且价格估价很高。 Despite robust growth, Anthem faces risks due to high client and geographical concentration and a pricey valuation.